ArticleJournal for immunotherapy of cancer2026
Differential cytokine architecture in patients treated with CART19 versus CART22.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundCytokine release syndrome (CRS) is a life-threatening toxicity of chimeric antigen receptor T-cell therapy (CART) for B-cell acute lymphoblastic leukemia (B-ALL). Lower rates of severe CRS have been reported in patients treated with CD22-directed CART (CART22) compared with those treated with CD19-directed CART (CART19).
methodsMore than 1,000 serum proteins were measured using a proximity extension assay on 40 patients treated with CART19 or CART22 and cytokines were compared. Single-cell (single-cell RNA-sequencing (scRNAseq)) was used to identify cellular and transcriptional differences between patients treated with CART19 and CART22. CART19-blast and CART22-blast interactions at the immune synapse (IS) were modeled in vitro.
resultsWe identified interleukin-10 (IL-10) as a critical endogenous modulator of CRS and demonstrated that previous treatment with CART is associated with increased serum IL-10 in the setting of subsequent relapse. Mechanistically, IL-10 induced higher interferon gamma expression and
conclusionsThese findings reveal IL-10 as a potent CRS-mitigating factor and support IL-10 enhancement strategies to improve the safety of CART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.